Thomapyrin CLASSIC by Sanofi S.A. - headache staple with combo analgesic

Thomapyrin CLASSIC sits in the palm like any other white tablet, but for many German consumers it is the go-to combo pill when a dull tension headache starts pressing behind the eyes. You swallow it with a glass of water, and a slightly bitter aftertaste reminds you that several active ingredients are at work.

Combination pain relief in one pill

Thomapyrin CLASSIC is an over-the-counter combination analgesic manufactured for the German market by Sanofi S.A., bringing together acetylsalicylic acid, paracetamol and caffeine in each tablet for the treatment of acute headache.

Each Thomapyrin CLASSIC tablet contains 250 mg acetylsalicylic acid, 200 mg paracetamol and 50 mg caffeine, a dosage mix that aims to tackle pain perception while enhancing the effect through the stimulant component.

Dosing, indication and everyday use

The recommended dose for adults and adolescents aged 12 years and older is one to two tablets as needed for acute headache, with repeat dosing possible after at least four hours, not exceeding six tablets per day according to the patient leaflet.

Thomapyrin CLASSIC is indicated specifically for acute tension-type headaches and migraine-like pain, and Sanofi emphasizes that the product is not intended for long-term daily use or for children under 12 because of acetylsalicylic acid content.

How Sanofi positions Thomapyrin

On Sanofi's German consumer health pages Thomapyrin sits among branded pain relief lines, with CLASSIC sharing shelf space with variants such as Thomapyrin INTENSIV, offering slightly different compositions and indications.

Sanofi consumer health executives like Céline Charveriat, who oversees aspects of the self-care business in Europe according to internal corporate presentations, describe headache remedies as a volume-driven yet highly regulated segment where brands have to balance efficacy claims with safety messaging.

Regulatory label and safety notes

Thomapyrin CLASSIC is classified as a pharmacy-only medication in Germany, meaning it is available without prescription but must be sold through pharmacies, where pharmacists can advise on dosage and interactions.

The package insert warns patients against using Thomapyrin CLASSIC in combination with other acetylsalicylic acid or paracetamol-containing medicines, and highlights contraindications such as stomach ulcers, severe liver impairment or known hypersensitivity to salicylates.

How the triple combination works

The acetylsalicylic acid portion acts as a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase and reduces prostaglandin synthesis, while paracetamol works mainly centrally, raising pain thresholds without significant anti-inflammatory action.

Caffeine in Thomapyrin CLASSIC is meant to enhance analgesic effects and counteract drowsiness; research cited in headache guidelines suggests that low-dose caffeine can moderately improve pain relief when combined with traditional analgesics, though sensitivity varies across patients.

Packaging, experience and branding

The Thomapyrin CLASSIC carton in German pharmacies is easy to spot: a blue and white design with a stylized head silhouette, conveying the headache focus in a way that feels clinical rather than flashy.

Open the blister and the tablets have a smooth coating, making them relatively easy to swallow; users often describe a neutral smell, which matters when someone with a migraine is sensitive to strong odors and wants medication that does not add sensory irritation.

Market presence in Germany

Thomapyrin as a brand has been present in the German market for several decades, and CLASSIC remains a core SKU in Sanofi's local pain portfolio, competing against single-ingredient OTC analgesics and other combination products like ibuprofen-plus-caffeine generics.

Market data from German pharmacy statistics show that combination headache analgesics still account for a meaningful share of OTC pain relief sales, even as some medical guidelines favor single substances; Sanofi leverages Thomapyrin's name recognition to defend shelf space.

Medical perspective and guideline context

Headache societies such as the Deutsche Migräne- und Kopfschmerzgesellschaft generally recommend limiting analgesic use to fewer than 10 days per month to minimize the risk of medication overuse headache, a warning that applies to products like Thomapyrin CLASSIC as well.

Doctors often see Thomapyrin CLASSIC as a pragmatic option for short-lived, self-limiting headaches when stronger prescription triptans or other migraine-specific drugs are not warranted, but they stress reading the leaflet carefully and respecting maximum daily doses.

Role within Sanofi's consumer portfolio

Sanofi, headquartered in Paris, has spent years reshaping its consumer healthcare business, including pain and allergy brands, with Thomapyrin CLASSIC representing a legacy asset in Germany that still delivers steady revenue despite intense competition.

In recent investor presentations, CEO Paul Hudson has pointed to consumer health as a cash-generating segment that helps fund R&D for prescription drugs; products like Thomapyrin CLASSIC thus sit quietly behind the scenes, supporting the balance sheet while not grabbing headlines.

Stock context and investor angle

For investors watching Sanofi S.A., Thomapyrin CLASSIC is one of many consumer health products that provide recurring cash flow alongside vaccines and specialty medicines; while not a driver of strategic transformation, it helps smooth earnings from quarter to quarter.

On Euronext Paris, the Sanofi S.A. share (ISIN FR0000120578) trades in euros and reflects this mix of innovative pharmaceuticals and established OTC brands like Thomapyrin CLASSIC.